Ann: Exercise and Expiry of Listed Options, page-3

Absolutely stunning result for the options, 77m/79m converted is amazing.

So another $4.8m in the bank must put us back up around $22m mark cash on hand.

With zero debt, a strong cash balance of over $20m with a burn of about $4m a year, with assets firing across the board and PTX-100 looking likely to move to a registrational trial later this year...Things are looking well and stabile for shareholders.

Yes the macro environment has been challenging, having it's effect on the chart and biotech sector in general. But during these times, all we can hope for is that the assets continue to deliver strong results and our cash balance remains robust...Which they both are.